Table 40: Product Profile - MS9 Table 41: MS9 SWOT Analysis, 2013 Table 42: Septin-9 CRC Screening Marketed Laboratory-Developed Tests Table 43:
|
|
|
- Emma Morrison
- 10 years ago
- Views:
Transcription
1 LIST OF TABLES 1.1 List of Tables Table 1: Initial Presenting Symptoms of Colorectal Cancer Table 2: Guideline Organization Recommendations for Non-Invasive Tests Table 3: TNM Classification System to Stage CRC Table 4: Stage Grouping for CRC Table 5: Stage II CRC Sub-Divisions Table 6: Stage III CRC Sub-Divisions Table 7: Stage IV CRC Sub-Divisions Table 8: Dukes System of CRC Classification Table 9: Treatment Guidelines for Colorectal Cancer Table 10: Surgical Options for Colorectal Cancer Table 11: Treatment Alternatives for CRC Table 12: Incident Cases of Colorectal Cancer, Ages =40 Years, Men and Women, N, Table 13: Costs of CRC Diagnosis, Treatment and Care Table 14: CRC Screening Test Segmentation Table 15: Guaiac Fecal Occult Blood Tests Product Profile Table 16: Guaiac FOB Test SWOT Analysis, 2013 Table 17: Immuno-FOB Tests Table 18: Product Profile - Lateral Flow Immunochemical Fecal Occult Blood Tests Table 19: Lateral Flow Immunochemical Fecal Occult Blood Tests SWOT Analysis, 2013 Table 20: Product Profile - Veda Lab Easy Reader (Lateral Flow Immunochemical Fecal Occult Blood Tests with Readers) Table 21: Veda Lab Easy Reader (Lateral Flow Immunochemical Fecal Occult Blood Tests with Readers) SWOT Analysis, 2013 Table 22: Fecal Occult Blood ELISA Products Table 23: Product Profile - Fecal Occult Blood ELISA Table 24: Immuno-FOB Test ELISA SWOT Analysis, 2013 Table 25: Commercially Available Immuno-FOB Agglutination Test Systems Table 26: Product Profile - Immuno-FOB Agglutination Tests Table 27: Immuno-FOB Agglutination Tests SWOT Analysis, 2013 Table 28: Key Mutations Associated with CRC Table 29: Key Stages of PCR Gene Test Table 30: Product Profile - PreGen Plus Table 31: PreGen Plus SWOT Analysis, 2013 Table 32: Product Profile - K-RAS, B-RAF, PIK3CA Array Table 33: K-RAS, B-RAF, PIK3CA Array SWOT Analysis, 2013 Table 34: Product Profile - Colonsentry Table 35: Colonsentry SWOT Analysis, 2013 Table 36: Product Profile - Detector C 2.0 Table 37: Detector C SWOT Analysis, 2013 Table 38: Product Profile - ColoSure Table 39: ColoSure SWOT Analysis, 2013
2 Table 40: Product Profile - MS9 Table 41: MS9 SWOT Analysis, 2013 Table 42: Septin-9 CRC Screening Marketed Laboratory-Developed Tests Table 43: Product Profile - ColoVantage/Septin-9 Table 44: ColoVantage/Septin-9 SWOT Analysis, 2013 Table 45: Product Profile - Tumor M2-PK Stool Test/2-in-1 Quick Test Table 46: Tumor M2-PK Stool Test/2-in-1 Quick Test SWOT Analysis, 2013 Table 47: Product Profile - Transferrin Assays Table 48: Transferrin Assays SWOT Analysis, 2013 Table 49: Major Reasons for Non-compliance with CRC Screening Table 50: Correlation of Fecal Occult Blood Test with Neoplasia Table 51: CRC Screening Tests Pipeline, 2012 Table 52: Product Profile - BST1 CRC Assay Table 53: BST1 CRC Assay SWOT Analysis, 2013 Table 54: Product Profile - Cologic Table 55: Cologic SWOT Analysis, 2013 Table 56: Product Profile - ColoGuard Table 57: ColoGuard SWOT Analysis, 2013 Table 58: Product Profile - Colon Cancer BEC Test Table 59: Colon Cancer BEC Test SWOT Analysis, 2013 Table 60: Product Profile - Colon MarCare Plex Table 61: Colon MarCare Plex SWOT Analysis, 2013 Table 62: Product Profile - Colox Table 63: Colox SWOT Analysis, 2013 Table 64: Product Profile - CRC Bacterial Signature Assay Table 65: CRC Bacterial Signature Assay SWOT Analysis, 2013 Table 66: Product Profile - CRC Breath Test Table 67: CRC Breath Test SWOT Analysis, 2013 Table 68: Product Profile - Epi procolon Table 69: Epi procolon Clinical Trials Table 70: Epi procolon SWOT Analysis, 2013 Table 71: ExiQon MicroRNA Sensitivity and Specificity Table 72: Product Profile - ExiQon microrna Test Table 73: ExiQon microrna Test SWOT Analysis, 2013 Table 74: Product Profile - Gemini CRC Biomarker Assay Table 75: Gemini CRC Biomarker Assay SWOT Analysis, 2013 Table 76: Product Profile - GenomicTree Methylated DNA Test Table 77: GenomicTree Methylated DNA Test SWOT Analysis, 2013 Table 78: Product Profile - Measure Table 79: Measure SWOT Analysis, 2013 Table 80: Product Profile - Metabiomics CRC Test Table 81: Metabiomics CRC Test SWOT Analysis, 2013 Table 82: Product Profile - mir-21 Test Table 83: mir-21 Test SWOT Analysis, 2013 Table 84: Product Profile - Oncolite-CR Table 85: Oncolite-CR SWOT Analysis, 2013
3 Table 86: Product Profile - PanC-Dx Table 87: PanC-Dx SWOT Analysis, 2013 Table 88: Uptake of Colonoscopy, Sigmoidoscopy and FOB Testing in the US Table 89: Projections for Virtual Colonoscopy use for CRC Screening Table 90: Key Mergers and Acquisitions during Table 91: Company Profile - Abbott Molecular Table 92: Abbott Molecular SWOT Analysis, 2013 Table 93: Company Profile - Alere Table 94: Alere SWOT Analysis, 2013 Table 95: Company Profile - Beckman Coulter Table 96: Beckman Coulter SWOT Analysis, 2013 Table 97: Company Profile - Biomarcare Technologies Table 98: Biomarcare Technologies SWOT Analysis, 2013 Table 99: Company Profile - Companion Dx Table 100: Companion Dx SWOT Analysis, 2013 Table 101: Company Profile - Eiken Chemical Table 102: Eiken Chemical SWOT Analysis, 2013 Table 103: Company Profile - Epigenomics Table 104: Epigenomics SWOT Analysis, 2013 Table 105: Company Profile - Exact Sciences Table 106: Exact Sciences SWOT Analysis, 2013 Table 107: Company Profile - ExiQon Table 108: ExiQon SWOT Analysis, 2013 Table 109: Company Profile - Fujirebio (Miraca Holdings) Table 110: Fujirebio SWOT Analysis, 2013 Table 111: Company Profile - GeneNews Table 112: GeneNews SWOT Analysis, 2013 Table 113: Company Profile - GenomicTree Table 114: GenomicTree SWOT Analysis, 2013 Table 115: Company Profile - Immunostics Table 116: Immunostics SWOT Analysis, 2013 Table 117: Company Profile - Kyowa Medex (Kyowa Hakko Kirin Group) Table 118: Kyowa Medex SWOT Analysis, 2013 Table 119: Company Profile - MDx Health Table 120: MDx Health SWOT Analysis, 2013 Table 121: Company Profile - Merck Millipore Table 122: Merck Millipore SWOT Analysis, 2013 Table 123: Company Profile - Metabiomics Table 124: Metabiomics SWOT Analysis, 2013 Table 125: Company Profile - Mode Diagnostics Table 126: Mode Diagnostics SWOT Analysis, 2013 Table 127: Company Profile - Oncocyte (Bio Time) Table 128: Oncocyte (Bio Time) SWOT Analysis, 2013 Table 129: Company Profile - Quest Diagnostics Table 130: Quest Diagnostics SWOT Analysis, 2013 Table 131: Company Profile - R-Biopharm
4 Table 132: R-Biopharm SWOT Analysis, 2013 Table 133: Company Profile - Randox Laboratories Table 134: Randox Laboratories SWOT Analysis, 2013 Table 135: Company Profile - ScheBo Biotech Table 136: Schebo Biotech SWOT Analysis, 2013 Table 137: Company Profile - SciMarket Technologies Table 138: SciMarket Technologies SWOT Analysis, 2013 Table 139: Company Profile - Siemens Healthcare Table 140: Siemens Healthcare SWOT Analysis, 2013 Table 141: Company Profile - Signature Diagnostics Table 142: Signature Diagnostics SWOT Analysis, 2013 Table 143: Company Profile - Sysmex Table 144: Sysmex SWOT Analysis, 2013 Table 145: Company Profile - Veda Lab Table 146: Veda Lab SWOT Analysis, 2013 Table 147: PreGen Plus Compared to Immuno-FOB Test Table 148: Potential Impacts of Restriction of Gene Patents Table 149: Major Events Affecting the Global In-Vitro CRC Screening Test Market Table 150: Sales Forecasts for In-vitro CRC Screening Tests in the US Market, Table 151: Forecasts for Numbers of In-vitro CRC Screening Tests, List of Figures Figure 1: Colorectal Cancer Staging Figure 2: US Trends in Colorectal Cancer Incidence, Figure 3: Total Costs of Colorectal Cancer to Society, Figure 4: Example of a Guaiac Fecal Occult Blood Card: Immunostics Hema-Screen Figure 5: Fecal Occult Blood Test Lateral Flow Device Architecture Figure 6: Biohit Colonview (example of immuno-fob test) Figure 7: Beckman Coulter Hemoccult-ICT (example of immuno-fob test) Figure 8: Veda Labs Easy Reader Immuno-FOB Test LFD Reader Figure 9: OC-Hemodia Agglutination FOB Test (manually performed) Figure 10: OC-Sensor/Diana FOB Test Sample Cartridge Figure 11: OC-Sensor/Diana FOB Test Instrument Figure 12: Fujirebio HemSp/MagStream HT Magnetic Agglutination Reaction Figure 13: Sentinel Diagnostic Sentifob Instrument Figure 14: Alere CI5 NS-Plus Instrument Figure 15: Orion Diagnostics Quikread FOB Test and Instrument Figure 16: Basic PCR Process Figure 17: MS9 PCR Response Curve Figure 18: Proposed ColoGuard Patient Stool Sample Collection Kit Figure 19: Exact Sciences Automated Sample Processing WorkStation Figure 20: Colox Kit Contents Figure 21: Measure Fecal Occult Blood Test Figure 22: PanC-Dx Multiplex Detection of CRC-specific Biomarker Figure 23: Uptake of FOB Testing in the US by Income,
5 Figure 24: US Sales Forecast for In-vitro CRC Screening Tests ($m), Figure 25: US Forecast for Numbers of In-vitro CRC Screening Tests, Figure 26: Share of Fecal Occult Blood Tests, by Brand, 2012 Figure 27: US Market Segmentation for In-vitro CRC Screening Tests, by Type, 2012 and 2019
MediPoint: In-Vitro Colorectal Cancer Screening Tests - Current and Future Players
Brochure More information from http://www.researchandmarkets.com/reports/2669701/ MediPoint: In-Vitro Colorectal Cancer Screening Tests - Current and Future Players Description: MediPoint: In-Vitro Colorectal
Epi procolon The Blood Test for Colorectal Cancer Screening
Epi procolon The Blood Test for Colorectal Cancer Screening Epi procolon is an approved blood test for colorectal cancer screening. The US Preventive Services Task Force, the American Cancer Society and
Early Detection of Colorectal Cancer Made Easy with a Blood Test
INFORMATION FOR PHYSICIANS Early Detection of Colorectal Cancer Made Easy with a Blood Test Epi pro Colon 2.0 : 2 nd Generation Septin 9 Test CRC SCREENING SAVES LIVES Colorectal cancer is a major health
Blood based colon cancer screening in Europe. Methylated Septin 9: Biomarker of malignant development in the colon Measured in Tissue and Plasma
Blood based colon cancer screening in Europe Methylated Septin 9: Biomarker of malignant development in the colon Measured in Tissue and Plasma Molnár, Béla M.D., PhD 2nd Dept. of Medicine Semmelweis University
Detecting Cancer in Blood. Company presentation
Detecting Cancer in Blood Company presentation Safe harbor statement Forward Looking Statements This communication contains certain forward-looking statements, including, without limitation, statements
Molecular Diagnostics in Cancer Testing
Product Sheet More information at http://www.biomarketgroup.com/market-research-report/molecular-diagnostics-in-cancertesting.html Molecular Diagnostics in Cancer Testing Published: 2015-AUG-01 Pages:
Blood-based SEPT9 Test in Colorectal Cancer Detection
Prof. JIANQIU SHENG, PENG JIN, YING HAN GI UNIT, BEIJING MILITARY GENERAL HOSPITAL Blood-based SEPT9 Test in Colorectal Cancer Detection A Report of Preliminary Study in China Disclosure of Interest: Nothing
Epigenomics AG Corporate Presentation
Epigenomics AG Corporate Presentation September 2013 www.epigenomics.com Safe Harbor Forward Looking Statements This communication contains certain forward-looking statements, including, without limitation,
Epigenomics AG. May 2015. www.epigenomics.com
Epigenomics AG May 2015 www.epigenomics.com Safe Harbor Forward Looking Statements This communication contains certain forward-looking statements, including, without limitation, statements containing the
colon cancer Talk to your doctor about getting tested for colon cancer. They know how to prevent and you can, too. Take a look inside.
2006, American Cancer Society, Inc. No. 243900 Rev.01/08 The American Cancer Society is the nationwide community-based voluntary health organization dedicated to eliminating cancer as a major health problem
Epigenomics AG. March 2015. www.epigenomics.com
Epigenomics AG March 2015 www.epigenomics.com Safe Harbor Forward Looking Statements This communication contains certain forward-looking statements, including, without limitation, statements containing
Craig Hallum Conference Investor Presentation
Craig Hallum Conference Investor Presentation Improving cancer outcomes with groundbreaking precision in molecular testing Paul Kinnon President and CEO Sept 2015 1 Forward-Looking Statements Certain statements
Real-Time PCR Single-Day Test Protocol Flexible Workflow. Rx Only. Detecting Cancer In Blood.
Real-ime PCR Single-Day est Protocol Flexible Workflow Rx Only Intended Use, Contraindicarions, Warnings, Precautions & Limitations...2 What is Epi procolon...3 Detecting Methylated Septin 9 DN...4 HeavyMethyl
TECHNOLOGIES, PRODUCTS & SERVICES for MOLECULAR DIAGNOSTICS, MDx ABA 298
DIAGNOSTICS BUSINESS ANALYSIS SERIES: TECHNOLOGIES, PRODUCTS & SERVICES for MOLECULAR DIAGNOSTICS, MDx ABA 298 By ADAMS BUSINESS ASSOCIATES MAY 2014. May 2014 ABA 298 1 Technologies, Products & Services
FDA Executive Summary. Prepared for the March 26, 2014 meeting of the Molecular and Clinical Genetics Panel. P130001 Epi procolon Epigenomics AG
FDA Executive Summary Prepared for the March 26, 2014 meeting of the Molecular and Clinical Genetics Panel P130001 Epi procolon Epigenomics AG INTRODUCTION This document is the FDA Executive Summary for
Miscellaneous Genetic and Molecular Diagnostic Tests
Miscellaneous Genetic and Molecular Diagnostic Tests Policy Number: 2.04.121 Last Review: 3/2016 Origination: 12/2014 Next Review: 3/2017 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
IMMUNOCHEMICALS - A Global Strategic Business Report
/wepdwukltuyot IMMUNOCHEMICALS - A Global Strategic Business Report 联 系 购 买 电 话 :010-82863480 公 司 名 称 : 佐 思 信 息 公 司 地 址 : 北 京 市 海 淀 区 苏 州 街 18 号 院 长 远 天 地 大 厦 A2 座 1008-1 室 (100080) 出 版 日 期 :April 2011
As Reported by the Senate Health, Human Services and Aging Committee. 127th General Assembly Regular Session Sub. S. B. No. 278 2007-2008 A B I L L
As Reported by the Senate Health, Human Services and Aging Committee 127th General Assembly Regular Session Sub. S. B. No. 278 2007-2008 Senator Coughlin Cosponsors: Senators Stivers, Mumper, Spada, Miller,
Roche Diagnostics Driving Personalized Healthcare
r his presentation contains certain forward-looking statements. hese forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
TriMark Publications (SAMPLE COPY, NOT FOR RESALE)
TriMark Publications November 2013 Volume: TMRMDC13-1101 MOLECULAR DIAGNOSTICS IN CANCER TESTING (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE
Worldwide Markets and Emerging Technologies for Point-of-Care Testing, 2013-2019. February 2015
Worldwide Markets and Emerging Technologies for Point-of-Care Testing, 2013-2019 February 2015 INTELAB CORPORATION MARKET AND TECHNOLOGY REPORTS Report 530 Copyright 2015 Worldwide Markets and Emerging
Colorectal Cancer: Preventable, Beatable, Treatable. American Cancer Society
Colorectal Cancer: Preventable, Beatable, Treatable American Cancer Society Reviewed January 2013 What we ll be talking about How common is colorectal cancer? What is colorectal cancer? What causes it?
Global Clinical Laboratory Testing Market Report: 2012 Edition
Brochure More information from http://www.researchandmarkets.com/reports/2165640/ Global Clinical Laboratory Testing Market Report: 2012 Edition Description: Clinical laboratory testing market is one of
COLORECTAL CANCER SCREENING
COLORECTAL CANCER SCREENING By Douglas K. Rex, M.D., FACG & Suthat Liangpunsakul, M.D. Division of Gastroenterology and Hepatology, Department of Medicine Indiana University School of Medicine Indianapolis,
Colorectal Cancer: Preventable, Beatable, Treatable. American Cancer Society
Colorectal Cancer: Preventable, Beatable, Treatable American Cancer Society Reviewed January 2016 What we ll be talking about How common is colorectal cancer? What is colorectal cancer? What causes it?
Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing
Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing These Are Hopeful Times for Lung Cancer Survivors When people first learn they have cancer, they are often afraid. But
Thank you very much for your interest in the Flu-FOBT Toolkit and Guide!
Thank you very much for your interest in the Flu-FOBT Toolkit and Guide! The Colorado Colorectal Screening Program s (The Program) Flu-FOBT initiative assists community health clinics with increasing colorectal
(SAMPLE COPY, NOT FOR RESALE)
TriMark Publications May 2016 Volume: TMRMDIDT16-0501 MOLECULAR DIAGNOSTICS IN INFECTIOUS DISEASE TESTING (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers
Cancer screening: cost-effectiveness. Endoscopic polypectomy: : CRC mortality. Endoscopic polypectomy: : CRC incidence
Cribado del cáncer (colorrectal): las pruebas de detección precoz salvan vidas Dr. Antoni Castells Servicio de Gastroenterología Hospital Clínic nic,, Barcelona ([email protected]) Conditions for a population-based
The Future of Clinical Chemistry and Laboratory Medicine, The Diagnostics Industry View
The Future of Clinical Chemistry and Laboratory Medicine, The Diagnostics Industry View Peng Yin, M.D., Ph.D., Director, Global Scientific Affairs Abbott Diagnostic Division (ADD) Agenda Lack of perceived
(SAMPLE COPY, NOT FOR RESALE)
TriMark Publications June 2016 Volume: TMRMDC16-0601 MOLECULAR DIAGNOSTICS IN CANCER TESTING (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE OF CONTENTS
Molecular Diagnostics Market Trends and Outlook Mark D. Hughes, Vice President Enterprise Analysis Corporation
Molecular Diagnostics Market Trends and Outlook Mark D. Hughes, Vice President Enterprise Analysis Corporation What this report contains: Overview of current global market size and forecast Examination
Colon Cancer. What Is Colon Cancer? What Are the Screening Methods?
Cancer of the colon or rectum (colorectal cancer) is the second most common cancer in the U.S. In fact, of all people born, 1 in 40 will die of the disease. What Is Colon Cancer? Colon cancer begins with
Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns
July 2013 Edition Vol. 7, Issue 7 Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns By Julie Katz, MPH, MPhil Biomarkers played a prominent role in the research presented in
The Forzani MacPhail Colon Cancer Screening Centre Frequently Asked Questions. What is the Forzani MacPhail Colon Cancer Screening Centre?
The Forzani MacPhail Colon Cancer Screening Centre Frequently Asked Questions What is the Forzani MacPhail Colon Cancer Screening Centre? The Forzani and MacPhail Colon Cancer Screening Centre (CCSC) is
Centre for Reviews and Dissemination
Centre for Reviews and Dissemination Diagnostic Accuracy and Cost-Effectiveness of Faecal Occult Blood Tests Used in Screening for Colorectal Cancer: A Systematic Review Promoting the use of research based
Diagnostics and Personalised Healthcare
Diagnostics and ersonalised Healthcare Daniel O Day Chief Operating Officer Roche Diagnostics Roche Diagnostics: Uniquely ositioned Revaluing in vitro Diagnostics Driving ersonalised Healthcare Roche Diagnostics
Randox Laboratories Ltd. - Product Pipeline Analysis, 2014 Update
Randox Laboratories Ltd. - Product Pipeline Analysis, 2014 Update Randox Laboratories Ltd. - Product Pipeline Analysis, 2014 Update Sector Publishing Intelligence Limited (SPi) has been marketing business
A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations
A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations Ce3, Inc. and Insight Genetics, Inc. Oncology Forum July 15, 2015 Agenda Introductions Definitions Regulations
Introduction to Pathology and Diagnostic Medicine
Harvard-MIT Division of Health Sciences and Technology HST.035: Principle and Practice of Human Pathology Dr. Badizadegan Introduction to Pathology and Diagnostic Medicine Spring 2003 What is pathology?
Overview of testing for Lynch syndrome/hnpcc
Overview of testing for Lynch syndrome/hnpcc This overview provides detailed information about interpreting MSI/IHC testing and genetic testing for Lynch syndrome/hnpcc. It is intended to be a reference
Hosts. New Methods for Treating Colorectal Cancer
Hosts Anees Chagpar MD Associate Professor of Surgical Oncology Francine MD Professor of Medical Oncology New Methods for Treating Colorectal Cancer Guest Expert: Scott, MD Associate Professor in the Department
Colorado Cancer Coalition Priorities: 2016 2018
Option 3 of 10: Screening & Early Detection: Screening Rates Presenter: Toni Panetta, MA, Director of Mission Programs, Susan G. Komen Colorado Goal 5: Objective 5.1: Objective 5.2 Focus Area: Focus Area:
Ontario Health Insurance Plan (OHIP) Billing Codes Information and Procedures for Claiming the Cumulative Preventative Care Bonus
Ontario Health Insurance Plan (OHIP) Billing Codes Information and Procedures for Claiming the Cumulative Preventative Care Bonus Eligible Patient Enrolment Model (PEM) physicians may receive Cumulative
Clinic Readiness Survey Leadership
Clinic Readiness Survey Leadership Date of interview: Organizational interview ID#: Interviewer: Interview modality: 1 phone 2 in-person STOP CRC is a program about colon health. As part of STOP CRC, we
Screening for Cancer in Light of New Guidelines and Controversies. Christopher Celio, MD St. Jude Heritage Medical Group
Screening for Cancer in Light of New Guidelines and Controversies Christopher Celio, MD St. Jude Heritage Medical Group Screening Tests The 2 major objectives of a good screening program are: (1) detection
VENTANA Digital Pathology. Reliable. Efficient. Comprehensive.
VENTANA Digital Pathology Reliable. Efficient. Comprehensive. In the quest to improve the lives of all patients afflicted with cancer, every second counts. Fast, informed clinical decisions are essential
Risk stratification for colorectal cancer especially: the difference between sporadic disease and polyposis syndromes. Dr. med. Henrik Csaba Horváth
Risk stratification for colorectal cancer especially: the difference between sporadic disease and polyposis syndromes Dr. med. Henrik Csaba Horváth Why is risk stratification for colorectal cancer (CRC)
Background and Company Performance... 3. Industry Challenges... 3. Product Family Attributes and Business Impact... 3. Conclusion...
Contents Background and Company Performance... 3 Industry Challenges... 3 Product Family Attributes and Business Impact... 3 Conclusion... 5 Significance of Product Leadership... 6 Understanding Product
Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019
Brochure More information from http://www.researchandmarkets.com/reports/3453273/ Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Description: About non-small cell lung cancer therapeutics
Nuevas tecnologías basadas en biomarcadores para oncología
Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS
guide Molecular Testing
[ tech ] guide Molecular Testing 1) What is the name of your company s molecular diagnostics testing product? Abbott Molecular Avellino Lab USA Inc biotheranostics Des Plaines, Ill (800) 554-7042 www.abbottmolecular.com
Rapid Progression from Tactical Buying to Global Strategic Sourcing. Vice President, Planning & Procurement
Rapid Progression from Tactical Buying to Global Strategic Sourcing Paul Anderson Vice President, Planning & Procurement Agenda: Strategic Sourcing Journey Life Technologies Overview Tactical Buying vs.
Examples of good screening tests include: mammography for breast cancer screening and Pap smears for cervical cancer screening.
CANCER SCREENING Dr. Tracy Sexton (updated July 2010) What is screening? Screening is the identification of asymptomatic disease or risk factors by history taking, physical examination, laboratory tests
This publication was developed and produced with funding from the Centers for Disease Control and Prevention under a cooperative agreement.
This publication was developed and produced with funding from the Centers for Disease Control and Prevention under a cooperative agreement. Suggested Citation Centers for Disease Control and Prevention.
JIANGSU CARTMAY INDUSTRIAL CO.,LTD www.labfurniture.asia mail: [email protected]
The basic layout, the main functions and instrumentation concept of micro Inspection Division laboratory, 1, Virology Laboratory 1. Functions: for the city to monitor the prevalence of HIV disease, dealing
Russia Genetic Testing Market Outlook to 2021
Russia Genetic Testing Market Outlook to 2021 GlobalData s new report, Russia Genetic Testing Market Outlook to 2021, provides key market data on the Russia Genetic Testing market. The report provides
2015 Medicare Physician Fee Schedule Putting the Pieces Together for GI Colleen M. Schmitt, MD, MHA, FASGE ASGE President
2015 Medicare Physician Fee Schedule Putting the Pieces Together for GI Colleen M. Schmitt, MD, MHA, FASGE ASGE President Glenn D. Littenberg, MD, MACP Chair, ASGE Practice Management Committee and CPT
Using genetic biomarkers to pre-identify oncology patients for clinical trials
White paper Quintiles Vantage Point Quintiles helped develop or commercialize all of the Top 30 bestselling oncology products of 2014 Oncology pre-profiling: Using genetic biomarkers to pre-identify oncology
Epi procolon. Finding Cancer Early. In Blood ANNUAL REPORT 2013
2013 Epi procolon Finding Cancer Early. In Blood ANNUAL REPORT 2013 CONTENTS Foreword by Dr. Thomas Taapken... 1 Report of the Supervisory Board... 6 Our stock... 11 Consolidated Management Report... 14
Diagnostics Division. Roland Diggelmann COO Roche Diagnostics. Picture
Diagnostics Division Roland Diggelmann COO Roche Diagnostics Picture HY 2013: Roche Group highlights HY 2013 performance Strong Pharma performance, driven by US; solid growth for Diagnostics 12% core EPS
Renal Cell Carcinoma (Event Driven)
Brochure More information from http://www.researchandmarkets.com/reports/2365661/ Renal Cell Carcinoma (Event Driven) Description: The Renal Cell Carcinoma market is highly lucrative. We anticipate that
Your Guide to Medicare s Preventive Services
Your Guide to Medicare s Preventive Services C E N T E R S F O R M E D I C A R E & M E D I C A I D S E R V I C E S This is the official government booklet with important information about: What disease
Molecular diagnostics is now used for a wide range of applications, including:
Molecular Diagnostics: A Dynamic and Rapidly Broadening Market Molecular diagnostics is now used for a wide range of applications, including: Human clinical molecular diagnostic testing Veterinary molecular
SMF Awareness Seminar 2014
SMF Awareness Seminar 2014 Clinical Evaluation for In Vitro Diagnostic Medical Devices Dr Jiang Naxin Health Sciences Authority Medical Device Branch 1 In vitro diagnostic product means Definition of IVD
How To Combine The Two Companies Into A Single Company
Announcement no. 22/2007 To OMX The Nordic Exchange, Copenhagen, and the press Vedbæk, November 27, 2007 EXIQON TO ACQUIRE ONCOTECH INC AND ENTER THE MARKET FOR CANCER MOLECULAR DIAGNOSTICS IN 2008 Summary:
PARTNERS IN HEALTH AT WORK
PARTNERS IN HEALTH AT WORK Editors: Damir Mazlagic, M.D., M.P.H., Medical Director; Patricia Haner, Practice Manager Contact: Berkshire Occupational health, 165 Tor Court, Pittsfield, MA 01240; Telephone:
Strategic Analysis of the U.S. Research Antibodies Market Presenting Opportunities for Market Share Gain
Strategic Analysis of the U.S. Research Antibodies Market Presenting Opportunities for Market Share Gain March 2012 Contents Section Slide Number Executive Summary 7 Market Overview 14 Research Antibodies
Preventive services process, Practice Solutions. Generating reminder letters with MD verification
Preventive services process, Practice Solutions. Generating reminder letters with MD verification By: Michelle Greiver MD CCFP Prepared for: North York Family Health Team, Summer 2012 Funding: Cancer Care
MEDICAL MALPRACTICE FACT BOOK
MEDICAL MALPRACTICE FACT BOOK - 1 - Firm Profile For over a decade, The Law Offices of Bruce M. Robinson have been dedicated to protecting the rights of victims who have been injured by the negligent and
Cancer Screening 22M 36% 56% Only 56% of uninsured women aged 50 74 are up-to-date with mammography screening. Colorectal Cancer Breast Cancer
July 2010 22M 22 million adults aged 50 75 need to be screened for colorectal cancer, and 7 million women aged 50 74 need to be screened for breast cancer. Cancer Screening Colorectal Cancer Breast Cancer
Point of Care HIV Viral Load Testing:
Point of Care HIV Viral Load Testing: Lesley Scott, Natasha Gous, Shuqi Chen *, Wendy Stevens Department of Molecular Medicine and Haematology University of the Witwatersrand, National Health Laboratory